The hallmarks of successful anticancer immunotherapy

doi:10.1126/scitranslmed.aat7807

Review

. 2018 Sep 19;10(459):eaat7807.

doi: 10.1126/scitranslmed.aat7807.

The hallmarks of successful anticancer immunotherapy

Lorenzo Galluzzi^{1

2

3}, Timothy A Chan^{4

5

6}, Guido Kroemer^{3

7

8

9

10

11

12}, Jedd D Wolchok^{6

13}, Alejandro López-Soto¹⁴

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY 10065, USA. deadoc@vodafone.it
² Sandra and Edward Meyer Cancer Center, New York, NY 10065, USA.
³ Université Paris Descartes/Paris V, 75006 Paris, France.
⁴ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
⁵ Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
⁶ Weill Cornell School of Medicine, New York, NY 10065, USA.
⁷ Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, 75006 Paris, France.
⁸ INSERM, U1138, 75006 Paris, France.
⁹ Université Pierre et Marie Curie/Paris VI, 75006 Paris, France.
¹⁰ Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Center, 94805 Villejuif, France.
¹¹ Pôle de Biologie, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France.
¹² Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden.
¹³ Department of Medicine, Parker Institute and Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
¹⁴ Departamento de Biología Funcional, Área de Inmunología, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33006 Oviedo, Spain. lopezsalejandro@uniovi.es

PMID: 30232229
DOI: 10.1126/scitranslmed.aat7807

Review

The hallmarks of successful anticancer immunotherapy

Lorenzo Galluzzi et al. Sci Transl Med. 2018.

. 2018 Sep 19;10(459):eaat7807.

doi: 10.1126/scitranslmed.aat7807.

Authors

Lorenzo Galluzzi^{1

2

3}, Timothy A Chan^{4

5

6}, Guido Kroemer^{3

7

8

9

10

11

12}, Jedd D Wolchok^{6

13}, Alejandro López-Soto¹⁴

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY 10065, USA. deadoc@vodafone.it
² Sandra and Edward Meyer Cancer Center, New York, NY 10065, USA.
³ Université Paris Descartes/Paris V, 75006 Paris, France.
⁴ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
⁵ Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
⁶ Weill Cornell School of Medicine, New York, NY 10065, USA.
⁷ Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, 75006 Paris, France.
⁸ INSERM, U1138, 75006 Paris, France.
⁹ Université Pierre et Marie Curie/Paris VI, 75006 Paris, France.
¹⁰ Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Center, 94805 Villejuif, France.
¹¹ Pôle de Biologie, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France.
¹² Department of Women's and Children's Health, Karolinska University Hospital, 17176 Stockholm, Sweden.
¹³ Department of Medicine, Parker Institute and Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
¹⁴ Departamento de Biología Funcional, Área de Inmunología, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias (IUOPA), Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33006 Oviedo, Spain. lopezsalejandro@uniovi.es

PMID: 30232229
DOI: 10.1126/scitranslmed.aat7807

Abstract

Immunotherapy is revolutionizing the clinical management of multiple tumors. However, only a fraction of patients with cancer responds to immunotherapy, and currently available immunotherapeutic agents are expensive and generally associated with considerable toxicity, calling for the identification of robust predictive biomarkers. The overall genomic configuration of malignant cells, potentially favoring the emergence of immunogenic tumor neoantigens, as well as specific mutations that compromise the ability of the immune system to recognize or eradicate the disease have been associated with differential sensitivity to immunotherapy in preclinical and clinical settings. Along similar lines, the type, density, localization, and functional orientation of the immune infiltrate have a prominent impact on anticancer immunity, as do features of the tumor microenvironment linked to the vasculature and stroma, and systemic factors including the composition of the gut microbiota. On the basis of these considerations, we outline the hallmarks of successful anticancer immunotherapy.

PubMed Disclaimer

Cited by

Pharmacogenomics for immunotherapy and immune-related cardiotoxicity.
Castrillon JA, Eng C, Cheng F. Castrillon JA, et al. Hum Mol Genet. 2020 Oct 20;29(R2):R186-R196. doi: 10.1093/hmg/ddaa137. Hum Mol Genet. 2020. PMID: 32620943 Free PMC article. Review.
Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment.
Yang Y, Wang Y. Yang Y, et al. Front Immunol. 2021 Apr 2;12:640369. doi: 10.3389/fimmu.2021.640369. eCollection 2021. Front Immunol. 2021. PMID: 33868269 Free PMC article. Review.
Biological drug and drug delivery-mediated immunotherapy.
Xiao Q, Li X, Li Y, Wu Z, Xu C, Chen Z, He W. Xiao Q, et al. Acta Pharm Sin B. 2021 Apr;11(4):941-960. doi: 10.1016/j.apsb.2020.12.018. Epub 2020 Dec 31. Acta Pharm Sin B. 2021. PMID: 33996408 Free PMC article. Review.
Associations between HIFs and tumor immune checkpoints: mechanism and therapy.
Liu J, Jiang Y, Chen L, Qian Z, Zhang Y. Liu J, et al. Discov Oncol. 2024 Jan 2;15(1):2. doi: 10.1007/s12672-023-00836-7. Discov Oncol. 2024. PMID: 38165484 Free PMC article. Review.
Delayed Effect of Dendritic Cells Vaccination on Survival in Glioblastoma: A Systematic Review and Meta-Analysis.
Cozzi S, Najafi M, Gomar M, Ciammella P, Iotti C, Iaccarino C, Dominici M, Pavesi G, Chiavelli C, Kazemian A, Jahanbakhshi A. Cozzi S, et al. Curr Oncol. 2022 Feb 4;29(2):881-891. doi: 10.3390/curroncol29020075. Curr Oncol. 2022. PMID: 35200574 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The hallmarks of successful anticancer immunotherapy

Affiliations

The hallmarks of successful anticancer immunotherapy

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources